Weight-Based Dosing for Antiepileptics and Antihistamines in Infants (1-12 Months)
ANTIEPILEPTIC DRUGS
First-Line Antiepileptics
Phenobarbital is the definitive first-line antiepileptic for infants 1-12 months old, with a loading dose of 20 mg/kg IV followed by maintenance of 3-5 mg/kg/day 1.
- Loading dose: 20 mg/kg IV (can use 15-20 mg/kg range)
- Maintenance: 3-5 mg/kg/day (do not exceed 5 mg/kg/day to avoid accumulation due to long half-life of 69-165 hours)
- Additional doses: If seizures persist, give additional 20 mg/kg IV 1
- Therapeutic plasma levels (15-30 mcg/mL) are reached within minutes of IV loading and remain stable for 48 hours 2
Important caveat: If channelopathy (KCNQ2/KCNQ3 mutations) is suspected due to positive family history, use phenytoin or carbamazepine as first-line instead 1.
Alternative first-line (less effective):
- Levetiracetam: 40 mg/kg IV loading, then additional 20 mg/kg if seizures continue 1
- Only 28% effective vs 80% for phenobarbital in head-to-head trial 1
- Consider as first-line only if cardiac disorders present
Second-Line Antiepileptics
For seizures not responding to phenobarbital, use phenytoin or levetiracetam as second-line 1.
- Phenytoin: 10-20 mg/kg IV, infused slowly 3
- Levetiracetam: 20 mg/kg IV (if not used first-line) 1
- Midazolam: 0.15-0.4 mg/kg IV (once or twice), then continuous infusion at 0.06-0.18 mg/kg/hour 3
- Lidocaine: 1-2 mg/kg IV (once or twice), then continuous infusion at 2-4 mg/kg/hour 3
Efficacy data: Midazolam (57.6% effective) outperforms lidocaine (41.7%) and phenytoin (39.0%) 3.
Third-Line Antiepileptics
Thiopental is the third-line agent for refractory seizures 3.
- Thiopental: 3-10 mg/kg IV, then continuous infusion at 2-5 mg/kg/hour 3
- 90.4% effective but requires intubation and mechanical ventilation 3
- Use only when first and second-line agents fail
Special Considerations for Infants
- Pyridoxine trial: If seizures are unresponsive to second-line agents without identified etiology, or if vitamin B6-dependent epilepsy suspected, trial pyridoxine as add-on therapy 1
- Dosing adjustments: Neonates and young infants may require shorter dosing intervals to maintain therapeutic levels 4
- ECMO support: Use upper limit of phenobarbital dosing range (5 mg/kg/day) 5
- Severe asphyxia: Use lower limit of phenobarbital dosing range (3 mg/kg/day) 5
ANTIHISTAMINES
Critical Limitation
The provided evidence does not contain guideline or drug label information for antihistamine dosing in infants 1-12 months old. The only antihistamine reference is from an anaphylaxis guideline 6 that focuses on epinephrine as first-line treatment and explicitly states antihistamines are second-line therapy only for anaphylaxis, not primary treatment.
Anaphylaxis Context Only
Epinephrine is first-line for anaphylaxis, not antihistamines 6.
- Epinephrine: 0.01 mg/kg IM (1:1000 solution) into anterolateral thigh
- Maximum 0.3 mg in children
- For infants, 0.1 mg or 0.15 mg auto-injector doses available (0.15 mg acceptable for infants >7.5 kg) 6
- Antihistamines are considered solely second-line therapy for anaphylaxis 6
No evidence-based dosing recommendations for first-, second-, or third-line antihistamines (oral or IV) in infants 1-12 months are provided in the available guidelines.
Key Clinical Pitfalls
- Do not delay phenobarbital for suspected channelopathy without positive family history—start phenobarbital immediately 1
- Do not use levetiracetam as first-line unless cardiac contraindications to phenobarbital exist (only 28% vs 80% efficacy) 1
- Do not exceed phenobarbital 5 mg/kg/day maintenance to avoid drug accumulation 2, 5
- Do not use antihistamines as first-line for anaphylaxis—epinephrine is the only appropriate first-line treatment 6
- Discontinue phenobarbital early (1-2 weeks) in acute provoked seizures responding to treatment to minimize exposure 1, 2